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Abstract
Lipedema is a chronic, progressive disorder of adipose tissue, found almost exclusively in women, that involves 
disproportionate subcutaneous fat depositions, leading to progressive and symmetric enlargement of the legs. 
The condition usually appears at puberty or in the third decade of life. Many patients report a family history of 
such disorder. The diagnosis is usually based on the physical examination and medical history. If left untreated, 
lipedema may result in secondary lymphatic dysfunction, physical impairment and mental problems, leading 
to significant damage to patient’s quality of life. The condition is frequently misdiagnosed as lymphedema or 
mistreated as obesity. Other than that, the differential diagnosis includes chronic venous insufficiency, consti-
tutional variability of the legs, lipohypertrophy, Dercum’s disease, Madelung’s disease. The treatment options 
include diet and compression therapy, conservative treatment of secondary edema and surgical interventions. 
There is an urgent need for further studies on the pathogenesis of lipedema, epidemiology, diagnostic criteria 
and possible curative treatment.
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Introduction
Lipedema was first described in 1940 by Allen 
and Hines as bilateral enlargement of the legs due to 
abnormal depositions of subcutaneous fat associated 
with often mild edema [1, 2]. Lipedema, as well as 
multiple symmetric lipomatosis (MSL) and Dercum’s 
disease (DD), has been classified to rare adipose dis-
orders (RADs) [3]. Even though the condition has not 
yet been registered in the International Classification 
of Diseases (ICD-10) of the World Health Organiza-
tion, the current knowledge indicates that lipedema 
is a clinical entity, distinct from lymphedema. Patients 
usually develop bilateral, symmetrical, non-pitting 
enlargement of lower extremities, disproportionately 
greater than that of the trunk and upper extremities. In 
a typical presentation, the feet are unaffected and the 
Stemmer sign is absent. Patients often report pain of 
affected areas, tenderness and spontaneous or minimal 
trauma-induced bruising [4]. The course of lipedema is 
variable. Patients may develop serious complications, 
which include lipolymphedema, orthopedic disorders, 
immobility-related obesity and major mental distress. 
Therefore, it is crucial that patients suffering from 
lipedema receive an accurate diagnosis as early as pos-
sible, followed by optimal information and treatment. 
In this article, the epidemiology, pathogenesis, clinical 
presentation, diagnostic findings, differential diagnosis 
and treatment are presented. The aim of this review is 
to increase the awareness and knowledge of lipedema 
among physicians resulting in optimizing management 
and care of patients with this condition. 
Epidemiology
No epidemiological data on the prevalence of 
lipedema is yet available. The studies from speciality 
lymphedema clinics estimate that 10–18% of referred 
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patients were eventually diagnosed with lipedema 
[5–7]. Other authors estimate that up to 11% of fe-
males may be affected [8]. Surely, there is a significant 
underestimate due to the failure of referral by physi-
cians and common misdiagnosis. 
Although a few cases of men with lipedema [2, 9, 10] 
have been reported in the literature, the condition 
affects almost exclusively females. 
Significant differences in prevalence in different parts 
of the world are noted, e.g. the condition is practically 
absent among women of Asian origin [11]. The most 
data concerning management of lipedema is obtained 
from Germany, where the diagnosis and treatment of 
this condition are well developed.
Pathogenesis and etiology
The etiology of lipedema remains uncertain. Several 
theories concerning this condition have been presented. 
Földi and Földi [12], based on their histological find-
ings, suggested that microangiopathy in the area of the 
affected adipose tissue results in higher permeability to 
proteins and increased capillary fragility. In the further 
course of this condition, impairment of lymph transport 
capacity by overgrown adipose tissue and excess of 
extravasated fluid induce fibrosis and lead to subsequent 
progression to lipolymphedema [13]. 
Amman-Vesti et al. described lymphatic microaneu-
rysms in lipedema patients suggesting the involvement 
of lymphatic system in lipedema pathogenesis [14].
Lymphatic system failure might contribute to fat 
deposition. Mice with heterozygous Prox-1 mutation 
present with lymphatic system failure and obesity [15]. 
Lymph itself was found to be a potent stimulator of 
adipogenesis [16]. 
Vascular endothelial growth factor (VEGF) is consid-
ered to be a potent inducer of angiogenesis. Siems et al. [17] 
discovered fourfold higher levels of plasma VEGF in 
lipedema patients. This may result in pathological 
angiogenesis and increased capillary fragility. Further 
studies reported high levels of both protein carbonyls 
and malonyldialdehyde (MDA), which are known indi-
cators of oxidative stress, representing an accelerated 
lipid peroxidation in lipoedematous tissue.
In other study, Suga et al. [18] analyzed differences 
between lipedema tissue and the nonaffected adipose 
tissue obtained from a patient with severe lipedema. Im-
munohistochemical findings proved edematous change, 
the presence of large adipocytes and crown-like struc-
tures (necrotizing adipocytes surrounded by infiltrating 
CD68+ macrophages) in lipedema tissue. Furthermore, 
the authors discovered proliferation of Ki67+ and 
CD34+ cells, which are identified as adipose-derived 
stem cells. The hypothesis has been presented that the 
increased proliferation of adipose stem cells leads to 
a rapid increase in adipogenesis, resulting in localized hy-
poxia, adipocyte necrosis and macrophage recruitment.
As a positive family history of lipedema is one of its 
characteristics, genetic inheritance has been studied. 
Child et al. [19] proposed, that lipedema is a genetic 
disorder with either X-linked dominant inheritance or 
autosomal dominant inheritance with sex limitation. 
Bano et al. [20] reported a case study that identifies 
a Pit-1 mutation in members of a family with lipedema. 
The condition has not been yet included in the 
Online Mendelian Inheritance in Man (OMIM) database 
for hereditary diseases. 
To fully understand the pathophysiological mecha-
nisms of lipedema further studies are urgently needed. 
Clinical presentation 
There are only few published criteria for lipedema 
diagnosis. On that basis, the diagnosis of lipedema de-
pends mainly on the clinical experience of the medical 
professionals. Physical examination should include 
thorough evaluation of extremities affected with the 
edema. Especially asymmetry or any other differences 
between the limbs should be noted. It is important to 
meticulously access the location, volume and nature of 
limb enlargement. Prior surgical interventions in the ex-
tremities and groin area should be documented [21]. Pa-
tients typically present bilateral, symmetrical increase of 
adipose tissue on the lower limbs. The condition affects 
buttocks, as well as hips, thighs and calves [10]. In the 
initial phase, the first sign could be the filling of the ret-
romalleolar sulcus, that is the disappearance of the con-
cave spaces on both sides of the Achilles tendon [22]. 
Characteristically, the feet are spared [23] with negative 
Stemmer sign. The fatty enlargement of the extremity 
begins abruptly above the malleolus. The visible demar-
cation between the normal and abnormal tissue near 
the ankle-distinct step-off — is accentuated, which is 
known as “cuff sign” [4]. That is an important morpho-
logic criterion of lipedema. In some patients, similar 
deposits develop in the upper limbs, with sparing of 
the hands. Although the majority of patients suffering 
from lipedema are overweight or obese, there are also 
some of normal weights. What differs lipedema from 
obesity is the disproportionate enlargement of the 
lower extremities in relation to the trunk and upper 
extremities. The weight loss has usually only limited 
influence on the disproportionate fat distribution. The 
fatty swelling is typically not reversible overnight or 
upon elevation of the extremity. The fatty tissue is 
tender under pressure and likely to develop hematomas 
even after the slightest trauma. Patients often report 
the sensations of heaviness and discomfort of the legs.
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There are five types of lipedema based on the area of 
accumulation of excessive subcutaneous adipose tissue:
Type I — buttocks and thighs.
Type II — extends to knees with the formation of fat 
folds on the inner side of the knees.
Type III — buttocks to ankles.
Type IV — involving the legs and arms.
Type V — lipo-lymphedema [24].
Meier-Vollrath and Schmeller [25] proposed a stag-
ing system to assess the severity of lipedema. In stage 
I the skin surface is normal with enlarged subcutis, on 
palpation, multiple small nodules (‘styrofoam balls’) 
can be distinguished. Stage II is associated with the 
development of bigger nodules (‘walnut- to apple-like 
indurations’). As a result, the overlying skin appears 
doughy, puckering and uneven (“mattress phenome-
non”). In stage III larger indurations and deforming fat 
deposits may develop and orange-peel appearance of 
the skin may be visible. 
Lipedema onset is typical during teenage years by 
the third decade of life but can occur at other times 
of hormonal change such as pregnancy or even men-
opause [19].
Large variability in the course of the condition is 
noted. Some patients develop only mild lipedema, 
which does not progress. Others show gradual and 
slow progression. Sudden exacerbations may be caused 
by the stressful situation, such as pregnancy or surgery 
[4]. Obesity is perceived as a major exacerbating factor 
in the course of lipedema. At any time the condition 
may be complicated by secondary lymphedema [26]. 
Furthermore, long-lasting lipedema linked with morbid 
obesity may lead to immobility-induced edema. With 
the progression of lipedema, the increased lower 
extremities weight may lead to joint damage causing 
orthopedic disorders (e.g. genu valgum, pes planus) and 
gait alternations with impaired mobility [7]. 
Diagnostic findings
There are no blood or urine biomarkers for li-
pedema. Although it is usually possible to diagnose 
lipedema based only on the clinical features and medical 
history, patients often undergo advanced radiologic 
and radionuclide imaging. Data provided from these 
investigations might be used for differential diagnosis 
and evaluation of the severity of lipedema. 
High-resolution cutaneous ultrasonography can 
be used to differentiate lipedema from lymphedema. 
Patients with lipedema have normal dermal thickness 
and echogenicity, whereas increased dermal thickness 
and decreased echogenicity are found in lymphedema 
patients [27]. Duplex examination (Doppler colour 
ultrasound) of lipedema reveals thickened subcutis with 
high echogenicity, while in lymphedema echodense, 
non-compressible areas are observed [7].
Computed tomography images provide high sensitiv-
ity and specificity of 100% for the diagnosis of lipedema. 
Typical scans show diffuse and homogenous lipomatous 
hypertrophy of subcutaneous tissue without skin ab-
normalities. Images of skin thickening, subcutaneous 
fluid accumulation, honeycomb appearance and muscle 
enlargement are characteristic of lymphedema [28].
Magnetic resonance imaging of lipedema shows 
normal skin thickness and lipomatous hypertrophy, 
while skin thickening, subcutaneous tissue thicken-
ing and honeycomb appearance are associated with 
lymphedema [29, 30]. Magnetic resonance lymphangi-
ography is considered useful when evaluating lymphatic 
insufficiency in lipedema/lipolymphedema patients [31].
Lymphoscintigraphy in lipedema patients shows 
normal or initially even increased lymphatic function 
in contrast to lymphedema [32, 33]. In long-lasting 
lipedema lymphoscintigraphy findings prove lymphatic 
insufficiency, often without morphologic abnormalities 
observed in lymphedema [34].
Amann-Vestii et al. [14] using fluorescence mi-
crolymphography with fluorescein isothiocyanate 
(FITC) proved that multiple microplymphatic aneu-
rysms of lymphatic capillaries in the diseased skin region 
of lipedema might be distinguishing finding in patients 
with lipedema. In lipedema lymphatic drainage visual-
ized in the microlymphography is typically intact or only 
unremarkably impaired, in contrast with lymphedema, 
where the drainage is significantly impeded [35].
Near-infrared fluorescence (NIRF) lymphatic im-
aging with indocyanine green (ICG) might be the next 
useful tool in accessing the lymphatic function in patients 
with edema of uncertain origin. NIRF lymphatic imaging 
phenotypes have already been established for patients 
with lymphedema and Dercum’s disease [36]. 
Differential diagnosis
The most important differential diagnoses of li-
pedema include lymphedema and obesity. In most 
cases, the thorough physical examination and extensive 
anamnesis are enough to establish the right diagnosis. 
Lymphedema refers to localized swelling, typically 
of one extremity, secondary to lymphatic dysfunction. 
Patients often report a history of erysipelas, cellulitis 
or prior malignancy followed by its treatment (surgery 
or radiation therapy). Secondary lymphedema of the 
lower extremities is estimated to occur in up to 25% 
of patients who underwent surgery and radiotherapy 
for the treatment of gynecological cancer [37]. Filariasis 
is also associated with secondary lymphedema in areas 
where the disease is endemic. Contrary to lipedema, 
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the swelling in lymphedema is typically unilateral and 
non-painful. Unlike in lymphedema [38, 39], the Stem-
mer’s sign (inability to pinch the base of the second toe) 
is negative in lipedema [40]. Furthermore, lymphedema, 
as opposed to lipedema, responds well to compres-
sion therapy [41]. The skin in patients suffering from 
lymphedema is often discoloured, warty and sclerotic, 
whereas the skin in lipedema remains intact. 
Often, in long-lasting patients, lipedema may be 
complicated by lymphedema or obesity. Therefore, it 
is crucial to know the patient’s historical symptoms and 
the course of the disease.
Distinguishing obesity from lipedema might come 
as challenging. What can be misleading, many patients 
with lipedema are seen with an apparently overweight 
BMI > 25 [19]. However, there are few diagnostic 
criteria, which denote obesity. Excess fatty tissue in 
obese patients appears in all parts of the body, unlike 
lipedema, where feet and hands are spared. In obese 
patients, the adipose tissue is distributed in a general-
ized pattern, whereas in lipedema the disproportion 
of fat accumulation between upper and lower body is 
noticeable. BMI might not be useful since it takes total 
weight into consideration but not the disproportionate 
distribution of the fatty tissue. However, the waist-hip 
ratio or waist-height ratio in obesity are abnormally 
elevated, unlike in lipedema. Obesity responds to re-
stricted dietary intake and exercising. On the contrary, 
lipedema patients often report aggressive dietary plans 
that fail to result in weight loss in the waist and lower 
extremities [10, 19]. Furthermore, the subcutaneous 
fatty tissue in obesity is not pain-sensitive. A more 
comprehensive list of differences between lipedema, 
lymphedema and obesity is presented in Table 1. 
Other, less common conditions should be consid-
ered in differential diagnosis as well.
Chronic venous insufficiency (phleboedema) causes 
hyperpigmentation, teleangiectasies, purpura, leg ulcers, 
pitting edema that decreases after bed rest and exercis-
ing — symptoms typically absent in lipedema patients. 
Edema responds well to compression therapy [42]. 
Varicose veins are often present in patients with 
lipedema, thus should not me considered as a distin-
guishing feature [2, 19].
Lipohypertrophy is a condition that is characterized 
by localized symmetrical fat depositions in buttocks, the 
upper or lower thighs or the lower calves [43]. Feet 
are spared. In contrast to lipedema, there is no pain 
on pressure, edema and malleolar fat pads are absent 
[6, 44]. The tendency to lipohypertrophy of the legs 
and gluteal region without displaying further signs of 
lipedema is often treated as a constitutional variant of 
normal leg form [45] and associated with ethnicity (e.g. 
women from the Mediterranean region). 
Madelung’s disease (MSL, multiple symmetric li-
pomatosis) is a condition that involves tumour-like 
non-encapsulated fatty deposits in the neck, upper 
trunk, upper back and occasionally the limbs. Typically, 
Madelung’s disease affects white, middle-aged men of 
Mediterranean origin who have a history of alcohol over-
use. Diabetes mellitus, lipid disorders, hypothyroidism 
and liver disease are common comorbidities [46, 47].
Table 1. Differential diagnosis of lipedema, lymphedema and obesity
Lipedema Lymphedema Obesity
Gender Females almost exclusively Males and females Males and females
Family history Frequent In primary lymphedema Frequent
Onset 10–30 years old (typically at puberty) Childhood (primary) 
Any age (secondary)
Childhood onward
Area affected Bilateral and symmetric involvement 
of legs, thighs, buttocks (feet spared); 
arms
In primary lymphedema lower 
extremities more frequent, typical 
asymmetric involvement
All parts of the body, 
symmetrical
Bruising yes no no
Pain Yes (tenderness or spontaneous pain) no no
Skin Normal consistency Thick, firm, sometimes reddish, 
brownish, warty with hyperke-
ratosis
Normal consistency
Stemmer’s sign Absent Often present Absent
Pitting edema Minimal Usually present in variable severity no
Effect of dieting Little effect on legs, arms and buttocks Little effect on affected extremity Symmetrical loss 
Effect of compression small Positive None
Skin infections Absent Common Absent
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Dercum’s disease (adiposis dolorosa) is a condition 
characterized by painful, easily bruised fatty tumours, 
which usually occurs in obese, post-menopausal women 
and is associated with type 2 diabetes, asthenia, weakness 
and mental phenomena such as depression, anxiety, con-
fusion and dementia. Adipose depositions usually locate 
in the area of limbs, trunk, buttocks and pelvic area, with 
a possible progression to circumscribed or general diffuse 
type [48–51]. Familial occurrence with dominant inher-
itance has been also reported [52]. Hansson, et al. [53] 
proposed Dercum’s disease classification including I. 
generalised diffuse form with widespread fatty tissue 
without clear lipomas, II. generalised nodular form with 
general pain in adipose tissue and intense pain in and 
around multiple lipomas, III. localised nodular form and 
IV. Juxta-articular form with painful lipomas associated 
with joints. The generalised diffuse form of Dercum’s 
disease shares many similarities with lipedema [36]. 
Hence, lipedema and Dercum’s disease are perceived by 
some experts as disorders in the same spectrum, if not 
the same condition in different stage of progression [3].
Acquired partial lipodystrophy (APL, Barraquer-Si-
mons syndrome) leads to symmetrical and progressive 
loss of subcutaneous adipose tissue starting at the face 
and spreading to the upper part of the body, sparing the 
legs. Due to similar phenotype, the condition might be 
confused with lipedema [54]. APL etiology is associated 
with autoimmune response to viral infection [55]. In 
APL patients there is a visible loss of subcutaneous 
adipose tissue (SAT) from the upper body to the waist, 
in contrast to lipdema, that is associated with normal 
or increased volume of SAT in these areas. 
Other conditions that cause edema of the lower 
extremities include idiopathic cyclic edema, edema due 
to internal disease (e.g. congestive heart failure, renal 
insufficiency), drug-induced edema and orthostatic 
edema. In contrast to lipedema, those usually involve 
pitting edema [4]. 
Treatment
As a causal treatment of lipedema is currently una-
vailable, the management of lipedema is symptom-based 
and aimed to reduce disability and patients’ complaints as 
well as prevent progression. Treatment of lipedema should 
also target factors that negatively influence the course of 
the condition, such as obesity, lymph- and phleboedema, 
poor physical activity, incorrect insight into the disease 
[11, 56]. Many patients will find the simple acknowledge-
ment of their complaints relieving since they often have 
been lengthily misdiagnosed as obese or mistreated as 
lymphedema. Ineffectiveness of restrictive diets, exercising 
and unsatisfactory effects of lymphatic therapy result in 
patients’ frustration, demotivation and disappointment. 
There is a little accessible data concerning proven 
lipedema treatments and lifestyle behaviours that 
may be beneficial. Therefore, education and proper 
information are fundamental in the management of 
lipedema patients. 
Lipedema is a chronic disease that is likely to cause 
pain, fatigue and deconditioning. That may result in de-
terioration in daily activity, shortage of physical exertion 
and increase in body weight [11]. Patients suffering from 
lipedema should be strongly and continuously encour-
aged to maintain physical activity, preferably aerobic 
exercises with low risk of injury such as speed walking, 
swimming and cycling [45]. Exercising activates muscle 
pump preventing lymphatic stasis, reducing edema 
formation and decreasing the risk of obesity. Dietician’s 
support is also beneficial. Even though dietary changes 
will not reduce the disproportionate fat distribution, 
they may reduce the risk of general obesity, improve 
prognosis and general well being.
Lipedema may be detrimental to mental health. 
Women affected by lipedema are likely to report low 
self-esteem, lack of confidence, depression, eating dis-
orders, self-harm tendencies or even suicidal thoughts. 
Furthermore, patients frequently state, that this condi-
tion has restricted their career, social and sex life [57]. 
Psychological support could be beneficial for some 
patients. Cognitive behaviour therapy is considered 
as a useful method in supporting the patient with this 
long-term condition in being proactive in managing 
their condition and helping patients with depression 
emotionally [58]. 
Treatment options include conservative approach 
and surgical interventions. Standard conservative 
therapy for lipedema can be performed with com-
plex decongestive therapy, which is based on clinical 
experience. Its elements are compression bandaging, 
manual lymph drainage (MLD), intermittent compres-
sion therapy with multi-chamber devices and adequate 
skin care. Complex decongestive therapy does not 
affect fat tissue [59]. Therefore, therapeutic effects for 
patients with simple lipedema with unaltered lymphatic 
drainage can be unsatisfactory. Nevertheless, consistent 
manual lymph drainage combined with multilayer and 
multicomponent compression bandaging may lead to 
a reduction of pain and tendency to develop hematomas 
[60, 61]. Furthermore, it has been proven to improve 
skin elasticity and restore veno-arteriolar reflex [62]. 
Conservative approach can highly contribute to the 
effective treatment of patients with lipolymphedema 
by preventing progression of the lymphatic component. 
Once the optimal effect of decongestive therapy is 
achieved, patients should be provided with flat knitted 
therapeutic compression hosiery to maintain the ben-
efits of the therapy [63]. 
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Surgical intervention remains the only available meth-
od to correct abnormal fat distribution. In contrast to the 
conservative treatment, it provides a reduction of mass. 
The most performed procedure is liposuction. In the 
past, this technique was perceived as contraindicated in 
lipedema patients due to the risk of iatrogenic damage to 
the lymphatic vessels [7]. The introduction of tumescent 
local anesthesia drastically reduced the risk of lymphatic 
impairment and significantly improved the outcomes of 
the liposuction [64, 65]. In tumescent liposuction, large 
amounts of fluids (saline, lidocaine, sodium bicarbonate 
and epinephrine) are infiltrated in the subcutaneous tissues 
and subsequently aspirated with vibrating microcannulas. 
The procedure leads to a distinct reduction of fat tissue. 
In addition to the positive cosmetic effect, it dramatically 
reduces symptoms such as bruising and pain. Further-
more, it has been proven, that it improves mobility. To 
maintain the reduced volume of the limb postoperatively 
patients should use compression garments [66] and keep 
a healthy lifestyle with balanced calorie intake and weight 
control. Although there are not well-recognized criteria 
of what is the optimal time in the course of lipedema to 
perform liposuction, latest studies showed that patients 
in stages II-III benefit the most from the procedure [65].
In some advanced cases of lipedema large localized 
deposits of fatty tissue are found. When situated on the 
legs it may result in severe mechanical limitations, lead-
ing even to inability to walk. In such cases, longitudinal 
excision (lumpectomy) is required [11].
Conclusion
Current knowledge indicates that lipedema is an 
underdiagnosed clinical entity. The most common 
differential diagnoses include obesity, lymphedema 
and constitutional variants of normal leg form. Further 
studies on its pathogenesis, epidemiology and effective 
treatment are urgently needed. Hard objective criteria 
for lipedema diagnosis should be established. Actions 
to promote awareness of this condition among medical 
professionals should be taken to provide patients with 
accurate treatment.
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